Literature DB >> 21977341

Venlafaxine for the treatment of hormonal therapy-induced hot flashes in a male patient.

Harmit Singh1, Ashish Sharma.   

Abstract

Entities:  

Year:  2011        PMID： 21977341      PMCID： PMC3184578          DOI： 10.4088/PCC.10l01039blu

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN： 2155-7780


× No keyword cloud information.
  6 in total

1.  Methodologic lessons learned from hot flash studies.

Authors:  J A Sloan; C L Loprinzi; P J Novotny; D L Barton; B I Lavasseur; H Windschitl
Journal:  J Clin Oncol       Date:  2001-12-01       Impact factor: 44.544

2.  Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.

Authors:  S K Quella; C L Loprinzi; J Sloan; P Novotny; E A Perez; P A Burch; S J Antolak; T M Pisansky
Journal:  J Urol       Date:  1999-07       Impact factor: 7.450

3.  Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.

Authors:  Jacques Irani; Laurent Salomon; Rostand Oba; Philippe Bouchard; Nicolas Mottet
Journal:  Lancet Oncol       Date:  2009-12-04       Impact factor: 41.316

4.  Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer.

Authors:  D A Schow; L G Renfer; T A Rozanski; I M Thompson
Journal:  South Med J       Date:  1998-09       Impact factor: 0.954

5.  Management of hot flashes in men with prostate cancer being treated with androgen deprivation therapy.

Authors:  Todd J Alekshun; Stephen G Patterson
Journal:  Support Cancer Ther       Date:  2006-10-01

6.  Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma.

Authors:  P Karling; M Hammar; E Varenhorst
Journal:  J Urol       Date:  1994-10       Impact factor: 7.450
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.